MSTN and proximal spinal muscular atrophy: This manuscript explores the role of myostatin in muscle, highlights the preclinical and clinical development of the myostatin inhibitor, taldefgrobep alfa and introduces the phase 3 RESILIENT trial of taldefgrobep alfa in SMA.